Plasmodium falciparum challenge

PreclinicalBiologic

RRadboud University Medical Center

Plasmodium falciparum challenge is one of 29 biologic programs targeting Malaria. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalariaActive, not recruiting

Plasmodium FalciparumCompleted

MalariaPreclinical

Active, not recruiting

Plasmodium FalciparumPreclinical

Completed

Competition

Competitive Landscape

79 competitors in Malaria

#DrugCompanyPhaseTrials

Dihydroartemisinin-Piperaquine

GSK

Phase 3

51 2

Rabies Vaccine

Novartis

Phase 3

8 3

Elimite

DDT MedTech, LLC

Approved

1 4

Krintafel

GGlaxo Dba Glaxosmithkline

Phase 3

3 5

Artemether-Lumefantrine (AL)

Novartis

Phase 3

11 6

Artesunate-Amodiaquine

Sanofi

Phase 3

19 7

R21/matrix-M

UUniversity of Oxford

Phase 3

4 8

Pyramax

SShin Poong Pharmaceutical Co. Ltd.

Phase 3

2 9

Biltricide

Bayer

Preclinical

1 10

Stelara

Johnson & Johnson

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malaria1 trial

Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

Completed·RRadboud University Medical Center·N/A·NCT01236612·25 enrolled

Plasmodium Falciparum1 trial

Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

Completed·RRadboud University Medical Center·N/A·NCT01218893·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Plasmodium falciparum challenge. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plasmodium falciparum challenge compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plasmodium falciparum challenge. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Radboud University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: RRadboud University Medical Center

Plasmodium falciparum challenge

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malaria1 trial

Plasmodium Falciparum1 trial

References

Drug Info

Quick Facts

Related News